Ignite Creation Date:
2024-05-06 @ 8:17 AM
Last Modification Date:
2024-10-26 @ 11:58 AM
Study NCT ID:
NCT02706626
Status:
TERMINATED
Last Update Posted:
2023-01-26
First Post:
2016-03-08
Brief Title:
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Sponsor:
Criterium Inc
Organization:
Criterium Inc
Organization Data
Organization:
Criterium Inc
Class:
INDUSTRY
Study ID:
ARI-AT-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Criterium Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Academic Thoracic Oncology Medical Investigators Consortium | INDUSTRY |
| University of Colorado Denver | OTHER |
| Duke University | OTHER |
| Takeda | INDUSTRY |
| Vanderbilt University | OTHER |
| University of Texas Southwestern Medical Center | OTHER |
| University of Pittsburgh | OTHER |
| Ohio State University | OTHER |
| Georgetown University | OTHER |